ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,699Medicare Part D Prescriptions Filled, Including Refills

Rank: 243 out of 680

$661K Total Retail Price of All Prescriptions

Rank: 178 out of 680

282 Patients Receiving at Least One Drug in Part D
39%Patients 65 Years and Older
90% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

7% of this provider’s 282 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 3,039 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
LEVOTHYROXINE SODIUM 444 118 1 2
OMEPRAZOLE 337 76 2 7
SIMVASTATIN 305 132 3 3
LISINOPRIL 251 69 4 5
METFORMIN HCL 225 107 5 8
NEXIUM 192 78 6 16
LACTULOSE 187 0 7 92
DIVALPROEX SODIUM ER 178 27 8 148
RISPERIDONE 157 16 9 80
ATORVASTATIN CALCIUM 142 43 10 11
BENZTROPINE MESYLATE 139 0 R 11 137
POTASSIUM CHLORIDE 138 30 12 14
POLYETHYLENE GLYCOL 3350 138 13 12 62
FUROSEMIDE 137 48 14 6
PROPRANOLOL HCL 130 34 15 145
LABETALOL HCL 130 73 15 158
AMLODIPINE BESYLATE 122 34 17 1
CRESTOR 108 25 18 25
HYDROCHLOROTHIAZIDE 99 51 19 9
CYMBALTA 97 45 20 46
LAMOTRIGINE 95 0 21 263
CLONIDINE HCL 94 34 22 36
IBANDRONATE SODIUM 93 24 23 288
METOPROLOL TARTRATE 92 23 24 12
ESCITALOPRAM OXALATE 90 16 25 45
CITALOPRAM HBR 86 23 26 22
KETOCONAZOLE 84 0 27 219
SERTRALINE HCL 84 44 27 28
LANTUS 79 20 29 49
FLUTICASONE PROPIONATE 79 37 29 41
PRAVASTATIN SODIUM 77 27 31 10
FELODIPINE ER 76 29 32 146
MELOXICAM 75 29 33 24
LISINOPRIL-HYDROCHLOROTHIAZIDE 71 41 34 37
CARVEDILOL 71 23 34 23
GABAPENTIN 69 24 36 15
OXCARBAZEPINE 68 24 37 304
SEROQUEL 68 13 37 123
ALENDRONATE SODIUM 68 24 37 32
SULFAMETHOXAZOLE-TRIMETHOPRIM 65 17 40 94
TRAZODONE HCL 65 22 40 48
LIPITOR 64 22 42 68
SEROQUEL XR 63 0 43 235
TOPIRAMATE 56 21 44 233
QUETIAPINE FUMARATE 54 19 45 64
DIOVAN 53 29 46 31
METOPROLOL SUCCINATE 52 23 47 13
WARFARIN SODIUM 52 26 47 20
GLYBURIDE 52 0 R 47 85
SINGULAIR 51 34 50 91
LOVAZA 50 0 51 119
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.